Please ensure Javascript is enabled for purposes of website accessibility

Regeneron, Sanofi Say Kevzara Will Now Only Be Tested in Sickest COVID-19 Patients

By Keith Speights – Apr 27, 2020 at 11:54AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The companies are halting clinical studies of the drug in those with severe cases of COVID-19 and focusing only on critical patients.

Regeneron Pharmaceuticals (REGN 0.83%) and Sanofi (SNY -0.75%) announced on Monday that a late-stage study evaluating Kevzara as a treatment for COVID-19 will be changed to only enroll COVID-19 patients in critical condition and only use a higher dose of the drug. The study previously included patients with severe cases of COVID-19 who weren't in critical condition and was testing two doses of Kevzara -- 200 milligrams and 400 milligrams. 

Why the changes were made

The  decision to make those changes came after the study's independent data monitoring committee (IDMC) reviewed data from the phase 2 part of the study along with preliminary data available from the phase 3 portion. The IDMC determined that Kevzara provided no clinical benefit compared to placebo for patients with severe cases of COVID-19.

COVID-19 printed on a blue background with two red plastic balls representing the coronavirus

Image source: Getty Images.

However, patients in critical condition appeared to have more positive outcomes after taking Kevzara. The data also showed that patients who were administered the higher 400 mg dose of the drug appeared to achieve better outcomes than those on the lower dose.

What's next

Regeneron and Sanofi are continuing to enroll patients in the ongoing phase 3 portion of the study, which already includes more than 600 patients in critical condition. The companies expect to announce results from the study by June.

Another late-stage study of Kevzara is also being conducted internationally, with enrollment of patients underway in Canada, France, Germany, Israel, Japan, Russia, and Spain. Regeneron and Sanofi anticipate reporting results from this second study in the third quarter.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$39.82 (-0.75%) $0.30
Regeneron Pharmaceuticals Stock Quote
Regeneron Pharmaceuticals
$745.68 (0.83%) $6.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.